Long-Term Outcomes in IgA Nephropathy

被引:193
作者
Pitcher, David [1 ,2 ]
Braddon, Fiona [1 ]
Hendry, Bruce [3 ]
Mercer, Alex [4 ]
Osmaston, Kate [1 ]
Saleem, Moin A. A. [5 ,6 ]
Steenkamp, Retha [1 ]
Wong, Katie [1 ,2 ]
Turner, A. Neil [7 ]
Wang, Kaijun [3 ]
Gale, Daniel P. P. [2 ]
Barratt, Jonathan [8 ,9 ,10 ]
机构
[1] UK Kidney Assoc, UK Renal Registry, Bristol, England
[2] UCL, Dept Renal Med, London, England
[3] Travere Therapeut Inc, San Diego, CA USA
[4] JAMCO Pharm Consulting, Stockholm, Sweden
[5] Univ Bristol, Bristol, England
[6] Bristol Royal Hosp Children, Bristol, England
[7] Univ Edinburgh, Edinburgh, Scotland
[8] Univ Leicester, Leicester, England
[9] Leicester Gen Hosp, Leicester, England
[10] Univ Leicester, Dept Cardiovasc Sci, Univ Rd, Leicester LE1 7RH, England
来源
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2023年 / 18卷 / 06期
关键词
chronic kidney disease; chronic kidney failure; end-stage kidney disease (ESKD); end-stage renal disease (ESRD); IGA nephropathy; kidney disease; nephropathy; proteinuria; CHRONIC KIDNEY-DISEASE; URINE PROTEIN; ASSOCIATION; ALBUMINURIA; REMISSION; FAILURE; RISK;
D O I
10.2215/CJN.0000000000000135
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background IgA nephropathy can progress to kidney failure, and risk assessment soon after diagnosis has advantages both for clinical management and the development of new therapeutics. We present relationships among proteinuria, eGFR slope, and lifetime risks for kidney failure. Methods The IgA nephropathy cohort (2299 adults and 140 children) of the UK National Registry of Rare Kidney Diseases (RaDaR) was analyzed. Patients enrolled had a biopsy-proven diagnosis of IgA nephropathy plus proteinuria >0.5 g/d or eGFR <60 ml/min per 1.73 m(2). Incident and prevalent populations and a population representative of a typical phase 3 clinical trial cohort were studied. Analyses of kidney survival were conducted using Kaplan-Meier and Cox regression. eGFR slope was estimated using linear mixed models with random intercept and slope. Results The median (Q1, Q3) follow-up was 5.9 (3.0, 10.5) years; 50% of patients reached kidney failure or died in the study period. The median (95% confidence interval [CI]) kidney survival was 11.4 (10.5 to 12.5) years; the mean age at kidney failure/death was 48 years, and most patients progressed to kidney failure within 10-15 years. On the basis of eGFR and age at diagnosis, almost all patients were at risk of progression to kidney failure within their expected lifetime unless a rate of eGFR loss <= 1 ml/min per 1.73 m(2) per year was maintained. Time-averaged proteinuria was significantly associated with worse kidney survival and more rapid eGFR loss in incident, prevalent, and clinical trial populations. Thirty percent of patients with time-averaged proteinuria of 0.44 to <0.88 g/g and approximately 20% of patients with time-averaged proteinuria <0.44 g/g developed kidney failure within 10 years. In the clinical trial population, each 10% decrease in time-averaged proteinuria from baseline was associated with a hazard ratio (95% CI) for kidney failure/death of 0.89 (0.87 to 0.92). Conclusions Outcomes in this large IgA nephropathy cohort are generally poor with few patients expected to avoid kidney failure in their lifetime. Significantly, patients traditionally regarded as being low risk, with proteinuria <0.88 g/g (<100 mg/mmol), had high rates of kidney failure within 10 years.
引用
收藏
页码:727 / 738
页数:12
相关论文
共 21 条
[1]   Association between albuminuria and proteinuria in the general population: the AusDiab Study [J].
Atkins, RC ;
Briganti, EM ;
Zimmet, PZ ;
Chadban, SJ .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2003, 18 (10) :2170-2174
[2]   Quantifying Duration of Proteinuria Remission and Association with Clinical Outcome in IgA Nephropathy [J].
Canney, Mark ;
Barbour, Sean J. ;
Zheng, Yuyan ;
Coppo, Rosanna ;
Zhang, Hong ;
Liu, Zhi-Hong ;
Matsuzaki, Keiichi ;
Suzuki, Yusuke ;
Katafuchi, Ritsuko ;
Reich, Heather N. ;
Cattran, Daniel .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (02) :436-447
[3]   A study of the relationship between albuminuria, proteinuria and urinary reagent strips [J].
Collier, Geraldine ;
Greenan, Marie Clare ;
Brady, Jennifer J. ;
Murray, Barbara ;
Cunningham, Sean K. .
ANNALS OF CLINICAL BIOCHEMISTRY, 2009, 46 :247-249
[4]   Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments [J].
Coppo, Rosanna ;
Troyanov, Stephan ;
Bellur, Shubha ;
Cattran, Daniel ;
Cook, H. Terence ;
Feehally, John ;
Roberts, Ian S. D. ;
Morando, Laura ;
Camilla, Roberta ;
Tesar, Vladimir ;
Lunberg, Sigrid ;
Gesualdo, Loreto ;
Emma, Francesco ;
Rollino, Cristiana ;
Amore, Alessandro ;
Praga, Manuel ;
Feriozzi, Sandro ;
Segoloni, Giuseppe ;
Pani, Antonello ;
Cancarini, Giovanni ;
Durlik, Magalena ;
Moggia, Elisabetta ;
Mazzucco, Gianna ;
Giannakakis, Costantinos ;
Honsova, Eva ;
Sundelin, B. Brigitta ;
Di Palma, Anna Maria ;
Ferrario, Franco ;
Gutierrez, Eduardo ;
Asunis, Anna Maria ;
Barratt, Jonathan ;
Tardanico, Regina ;
Perkowska-Ptasinska, Agnieszka .
KIDNEY INTERNATIONAL, 2014, 86 (04) :828-836
[5]  
Global Health Observatory data repository, LIF EXP HLTH LIF EXP
[6]   Life Expectancy for Patients From the Southeastern United States With IgA Nephropathy [J].
Hastings, M. Colleen ;
Bursac, Zoran ;
Julian, Bruce A. ;
Baca, Emanuel Villa ;
Featherston, Jennifer ;
Woodford, Susan Y. ;
Bailey, Lisa ;
Wyatt, Robert J. .
KIDNEY INTERNATIONAL REPORTS, 2018, 3 (01) :99-104
[7]   Association of Treatment Effects on Early Change in Urine Protein and Treatment Effects on GFR Slope in IgA Nephropathy: An Individual Participant Meta-analysis [J].
Inker, Lesley A. ;
Heerspink, Hiddo J. L. ;
Tighiouart, Hocine ;
Chaudhari, Juhi ;
Miao, Shiyuan ;
Diva, Ulysses ;
Mercer, Alex ;
Appel, Gerald B. ;
Donadio, James, V ;
Floege, Jurgen ;
Li, Philip K. T. ;
Maes, Bart D. ;
Locatelli, Francesco ;
Praga, Manuel ;
Schena, Francesco P. ;
Levey, Andrew S. ;
Greene, Tom .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2021, 78 (03) :340-+
[8]   Early Change in Urine Protein as a Surrogate End Point in Studies of IgA Nephropathy: An Individual-Patient Meta-analysis [J].
Inker, Lesley A. ;
Mondal, Hasi ;
Greene, Tom ;
Masaschi, Taylor ;
Locatelli, Francesco ;
Schena, Francesco P. ;
Katafuchi, Ritsuko ;
Appel, Gerald B. ;
Maes, Bart D. ;
Li, Philip K. ;
Praga, Manuel ;
Del Vecchio, Lucia ;
Andrulli, Simeone ;
Manno, Carlo ;
Gutierrez, Eduardo ;
Mercer, Alex ;
Carroll, Kevin J. ;
Schmid, Christopher H. ;
Levey, Andrew S. .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2016, 68 (03) :392-401
[9]   Mortality in IgA Nephropathy: A Nationwide Population-Based Cohort Study [J].
Jarrick, Simon ;
Lundberg, Sigrid ;
Welander, Adina ;
Carrero, Juan-Jesus ;
Hoijer, Jonas ;
Bottai, Matteo ;
Ludvigsson, Jonas F. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2019, 30 (05) :866-876
[10]   Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population [J].
Le, WeiBo ;
Liang, ShaoShan ;
Hu, YangLin ;
Deng, KangPing ;
Bao, Hao ;
Zeng, CaiHong ;
Liu, ZhiHong .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 (04) :1479-1485